Table 2. HIV-1 drug resistance in ARV-naïve subjects with primary HIV-1 infection.

2a: OLA versus consensus sequencing of plasma				2b: OLA versus consensus sequencing of PBMC				2c: Consensus sequencing of plasma versus PBMC				2d: OLA of plasma versus PBMC
p = .0005		OLA		p = .002		OLA		p = 1.0		PBMCs		p = 1.0		PBMCs
		−	+			−	+			−	+			−	+
sequencing	−	83	12	sequencing	−	81	13	plasma	−	94	1	plasma	−	72	11
	+	0	4		+	1	4		+	0	4		+	10	6

ARV: antiretroviral; OLA: oligonucleotide ligation assay; PBMC: peripheral blood mononuclear cells.

+ = subjects with ≥1 mutation or mixture.

− = subjects without mutations or with indeterminate results.

Numbers represent subjects in whom HIV-1 drug resistance was/was not detected in plasma and PBMC specimens that had been obtained a median of 29 (IQR 19–66) and 31 (IQR 19–66) days after HIV-1 infection, respectively; all specimens were collected within six months of infection. McNemar's exact tests compare only subjects with discordant results (indicated in bold).